Development of a trispecific fusion protein based on angiotensin-converting enzyme 2, glycoprotein 130, and tumor necrosis factor receptor 2 as a promising therapeutic for COVID-19
基于血管紧张素转化酶2、糖蛋白130和肿瘤坏死因子受体2的三特异性融合蛋白的开发,有望成为治疗COVID-19的有效疗法。
期刊:Molecular Biomedicine
影响因子:10.1
doi:10.1186/s43556-025-00320-4
Qiao, Yongfeng; Han, Yanjun; Zhao, Lu; Gao, Wenjing; Hu, Hong; Su, Chao; Zheng, Anqi; Sun, Junqing; Tian, Mingxiong; Wu, Yarong; Bai, Lianmei; Lei, Yuping; Wu, Jiahao; Zhang, Weibing; Han, Pu; Li, Xiaoyu; Dong, Chunbo; Wang, Haidong; Liu, Zhida; Han, Pengcheng